Cannabis Product Information

Cannabigerol (CBG)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Not on controlled substance list.
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
Cannabidiolic Acid (CBDA)
INDICATIONS AND USAGE
No FDA (US) indication. Not well studied. Useful as an anti-emetic. May decrease cancer cell growth.
CONTRAINDICATIONS
Unkown
WARNINGS AND PRECAUTIONS
Unkown
ADVERSE REACTIONS
Unkown
DRUG INTERACTIONS
Unkown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Not studied
Geriatric use
Not studied
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Not on controlled substance list.
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
Tetrahydrocannabinol (THC)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Schedule 1.
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Binds to the CB1 receptor which is thought to underlie is actions in brain.
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Oral, vaporized, smoked
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabichromene (CBC)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabinol (CBN)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabielsoin (CBE)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
nabilone (Cesamet®)
INDICATIONS AND USAGE
FDA (US) approved for chemotherapy induced nausea and vomiting in cancer patients; Schedule 2; synthetic delta 9 THC
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Schedule 2
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
synthetic CB1 agonist
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
CLINICAL PHARMACOLOGY
Unknown
rimonabant (Ecopipam®, Acomplia®)
INDICATIONS AND USAGE
Available in Europe since 2006 for use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors. Not approved in the US.
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
useful as an anti-obesity agent
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabis (plant material containing a mixutre of cannabinoids)
INDICATIONS AND USAGE
No FDA (US) indication
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
US DEA schedule 1 controlled substance; recreationally legal in Canada; legal in 29 US states.
Abuse
Schedule 1 due to percieved abuse potential; Cannabis use disorder (CUD)
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
activates dopamine neurons in the ventral tegmental nucleus; positron emmission tomographic increases in cerebsl blood flow in right frontal region, insula, temporal poles anterior cingulate paraliimbe regions with decreased cerebral blood flow in auditory, visual, and parietal cortices and thalamus; increases dopamine release in nucleus accumbens; potentiates the antinociceptive effects of morphine
EFFICACY
may relieve
PREPARATIONS AVAILABLE
oral; vaporized, smoked
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
impairs performance on tests balance and fine motor; oontrol; causes users to seek isolation and become immobile; impairs short term memory and attention; distortion of time auditory hallucinations; impairs cognitive function; increases appetire, particularly for sweet foods; tingling sensation, dizziness, lightheadedness; quickened mental associations; euphoria, relaxation, calming effect, dreamlike state, discnnection from reality, sleep; paranoia, amotivation /. laziness; acute withdrawal may cause craving, decreased appetiet, sleep disturbance, weight loss, anger, aggression, irritability, aggression, restlessness, and strange dreams;dry. mouth, dry eyes, urinary retention constipation (with chronic use); enhanced visual and audiatory perception;; depersonalization rerealization;
CLINICAL PHARMACOLOGY
oral preparations have slower onset of action; peak effects via smoking occur in about 60 minutes; infectious laughter;; alleviates depressed mood; may cause depression; panic attacks; impairs vigilance; may impair sustained focussed, sustained selective and divided attention
nabiximols (Sativex®)
INDICATIONS AND USAGE
In Canada for pain in advanced cancer and multiple sclerosis; in New Zealand and some countries in Europe for spacticity associated with MS
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabidivarin (CBDV)
INDICATIONS AND USAGE
none; under investigation for autism and partial epilepsy; has received orphan drug status for Rett syndrome.
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
phase 2 cinical trials of GWP42006, primarily CBDV with other cannabinoids, did not meet primary endpoint for partial seizures.
dronabinol (Marinol®)
INDICATIONS AND USAGE
FDA (US) approved for appetite stimulation in acquired immunodeficiency syndrome (AIDS) related wasting syndrome
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
tachycardia, hypertension, lethargy, nausea, irritability, chest pain, hallucination, and confusion; A 16-year-old male presented to the emergency department with chest pain after smoking a synthetic cannabinoid from a vape pen. He had rising troponin I levels, and his exercise stress echocardiogram showed distal apical and septal hypokinesis that resolved at six-month follow-up (Cureus. 2017 Nov; 9(11): e1899.)
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
In the US solutions containing dronabinol are classifed as a schedule II.
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
synthetic dela 9 THC
EFFICACY
Unknown
PREPARATIONS AVAILABLE
orala synthetic THC preparation
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabinodiol (CBDL)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabicyclol (CBL)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown
cannabidiol (CBD), (Epidiolex®)
INDICATIONS AND USAGE
US FDA approved for seizures associated with Lennox Gastaut and Dravet syndromes in patients 2 years and older. Compassionate use evidence suggests CBD is useful in partial onset seizures in children with refractory epilepsy, seizures associated with tuberous sclerosis and generalized seizures in adults.
CONTRAINDICATIONS
None
WARNINGS AND PRECAUTIONS
montitor liver function tests and billirubin at 1, 3 and 6 months of treatment onset
ADVERSE REACTIONS
Somnolence / sedation, increased by clobazam, tends to diminish over time. Decreased appetite, weight loss, ataxia, diarrhea, fatigue, malaise, rash, insomnia, hypersomnia. May increase the risk of suicidal thoughts or behavior.
DRUG INTERACTIONS
CBD may lower the serum levels of clobazam, rufinamide, and VPA. CBD inhbits CYP2C19 and may increase serum levels of N-desmethyl clobazam. May inhibit CYP2C9, 2C8, and 1A2, UgT1A9 and UGT287.
USE IN SPECIFIC POPULATIONS
Pregnancy
There are no adequate and well–controlled studies in pregnant women. This would suggest that CBD fits into category C, meaning human studies are lacking. Pregnancy registry: Patients are advised to enroll in the Sativa Science pregnancy registry. Information is available on this web site.
Nursing Mothers
Unknown
Pediatric use
Expanded access studies and clinical trials (GW Pharmacueticals) support efficacy in the pediatric population (EXPAND)
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Metabolized by CYP3A4 and 2C19. Increased AST / ALT levels in patients taking valproic acid. 7-OH-CBD is an active metabolite. >90% protein bound.
DRUG ABUSE AND DEPENDENCE
Controlled substance
CBD is a Schedule V controlled substance in the US with low abuse potential. CBD is available without a prescription in those states with medical marijuana laws.
Abuse
The abuse potential of CBD is minimal as it is not thought to have any significant psychotropic effects.
Dependence
Not thought to cause dependence.
OVERDOSAGE
Signs and symptoms of overdosage
somnalence, sedation, nausea
Treatment or management of overdose
taper or stop the drug depending on the clinical severity
MECHANISM OF ACTION
Unknown. Possible mechanisms: may block the bi-directional purine transporter resulting in elevated synaptic levels of adenosine, a potent endogenous anti-convulsant, which inhibits neurotransmitter release via blockade of pre-synaptic calcium influx. May act through an orphan G-protein coupled receptor such as GPR55. Decreases cytokine production in animals. Agonist at transient receptor potential vanilloif receptor (TRPV1).
EFFICACY
48% mean seizure reduction at 3 months in 18 patients with TS and medically refractory epilepsy enrolled in an expanded access study. Median baseline seizure frequency was 22. After 3 months the median seizure frequency decreased to 13.3, or 48.8 %, with 50% responder rates overall of about 50%. Of those patients on clobazam, the responder rate was 58.3%. Hess et al, Epilepsia, 2016;57 (10):1617-1624. Inhibits anxiety produced by THC. Increases sleep duration in insomniacs.
PREPARATIONS AVAILABLE
Liquid, oil
DOSING AND ADMINISTRATION
Varies depending on the disease; see disease specific dosing guidelines. For LGS and Dravet, 2.5 mg / Kg BID initially up-titrated as tolerated with maintenance dose of 10-20 mg / Kg / day, BID. May take with our without food, but patient must be consistent. May need to reduce dose with hepatic impairment.
SIDE EFFECTS
Drowsiness, ataxia, diarrhea
CLINICAL PHARMACOLOGY
Reduces nabilone (CB1 agonist) impairment of binocular depth inversion
cannabitriol (CBT)
INDICATIONS AND USAGE
Unknown
CONTRAINDICATIONS
Unknown
WARNINGS AND PRECAUTIONS
Unknown
ADVERSE REACTIONS
Unknown
DRUG INTERACTIONS
Unknown
USE IN SPECIFIC POPULATIONS
Pregnancy
Unknown
Nursing Mothers
Unknown
Pediatric use
Unknown
Geriatric use
Unknown
Patients with renal impairment
Unknown
Patients with hepatic impairment
Unknown
DRUG ABUSE AND DEPENDENCE
Controlled substance
Unknown
Abuse
Unknown
Dependence
Unknown
OVERDOSAGE
Signs and symptoms of overdosage
Unknown
Treatment or management of overdose
Unknown
MECHANISM OF ACTION
Unknown
EFFICACY
Unknown
PREPARATIONS AVAILABLE
Unknown
DOSING AND ADMINISTRATION
Unknown
SIDE EFFECTS
Unknown
CLINICAL PHARMACOLOGY
Unknown